MEYNIER , Jonathan

Summary Introduction Loss of response to golimumab occurs in nearly 40% of patients with ulcerative colitis (UC). Unlike others anti‐TNF, no study has reported a correlation between serum golimumab level and response to drug intensification. The objective of this study was to evaluate the effectiveness and safety of golimumab intensification...

Introduction: Loss of response to golimumab occurs in nearly 40% of patients with ulcerative colitis (UC). Unlike others anti-TNF, no study has reported a correlation between serum golimumab level and response to drug intensification. The objective of this study was to evaluate the effectiveness and safety of golimumab intensification and to...